What Is Dyne Therapeutics, Inc. (DYN) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Dyne Therapeutics, Inc.'s intrinsic value is estimated at $13.31, suggesting the stock is overvalued at its current price of $23.64. With 8 out of 10 models flagging downside (-43.7% average return), the market may be pricing in unsustainable growth. Notably, First Chicago sees the most upside at +26.1% (fair value: $29.82), while ML-RIV is the most conservative at -94.3% ($1.34). The spread between these extremes — +120.5% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About DYN?
10 of 13 models are currently active for DYN. Of these, 2 models suggest upside while 8 models suggest overvaluation. The Bayesian DCF estimates DYN's intrinsic value at $7.73, implying -67.3% downside from the current price. See which stocks rank higher →
How Does DYN Rank in Pharmaceutical Preparations?
Among 440 Pharmaceutical Preparations stocks, DYN ranks #219 by Quality of Company score. CirclFi's QOC score of 5.0/10 evaluates 32 fundamental signals. A score of 5.0 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
As a healthcare company, Dyne Therapeutics, Inc. operates in a sector where patent cliff exposure is a critical driver of valuation. Investors evaluating DYN should weigh these sector-specific dynamics alongside our model-derived fair values.
Is DYN a Value Trap?
CirclFi's Value Trap algorithm assigns DYN a score of 6/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
10 of 13 models are active for Dyne Therapeutics, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, Dyne Therapeutics, Inc. is rated at 5.0/10. This moderate-tier score shows mixed signals across our quality framework with notable weaknesses.
The gap between the most bullish and bearish model spans +120.5% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every DYN valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across DYN's 10 active models, average confidence is 40%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad